Application 210329
- Type
- ANDA
- Sponsor
- JUBILANT GENERICS
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | TADALAFIL | TADALAFIL | TABLET;ORAL | 2.5MG | No | No |
| 002 | TADALAFIL | TADALAFIL | TABLET;ORAL | 5MG | No | No |
| 003 | TADALAFIL | TADALAFIL | TABLET;ORAL | 10MG | No | No |
| 004 | TADALAFIL | TADALAFIL | TABLET;ORAL | 20MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A210329-001 | TADALAFIL | TADALAFIL | 2.5MG | TABLET / ORAL | AB1 | 2026-05-15 | |
| A210329-002 | TADALAFIL | TADALAFIL | 5MG | TABLET / ORAL | AB1 | 2026-05-15 | |
| A210329-003 | TADALAFIL | TADALAFIL | 10MG | TABLET / ORAL | AB1 | 2026-05-15 | |
| A210329-004 | TADALAFIL | TADALAFIL | 20MG | TABLET / ORAL | AB1 | 2026-05-15 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A210329-001 | AB1 |
| A210329-002 | AB1 |
| A210329-003 | AB1 |
| A210329-004 | AB1 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A210329-001 | TADALAFIL | 2.5MG | TABLET / ORAL | AB1 | 2026-05-15 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A210329-002 | TADALAFIL | 5MG | TABLET / ORAL | AB1 | 2026-05-15 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A210329-003 | TADALAFIL | 10MG | TABLET / ORAL | AB1 | 2026-05-15 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A210329-004 | TADALAFIL | 20MG | TABLET / ORAL | AB1 | 2026-05-15 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A210329-001 | TADALAFIL | 2.5MG | TABLET / ORAL | AB1 | 2026-05-15 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A210329-002 | TADALAFIL | 5MG | TABLET / ORAL | AB1 | 2026-05-15 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A210329-003 | TADALAFIL | 10MG | TABLET / ORAL | AB1 | 2026-05-15 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A210329-004 | TADALAFIL | 20MG | TABLET / ORAL | AB1 | 2026-05-15 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A210329-001 | TADALAFIL | 2.5MG | TABLET / ORAL | AB1 | 2026-05-15 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A210329-002 | TADALAFIL | 5MG | TABLET / ORAL | AB1 | 2026-05-15 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A210329-003 | TADALAFIL | 10MG | TABLET / ORAL | AB1 | 2026-05-15 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A210329-004 | TADALAFIL | 20MG | TABLET / ORAL | AB1 | 2026-05-15 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A210329-001 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A210329-002 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A210329-003 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A210329-004 | AB1 | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A210329-001 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A210329-002 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A210329-003 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A210329-004 | AB1 | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A210329-001 | AB1 | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A210329-002 | AB1 | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A210329-003 | AB1 | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A210329-004 | AB1 | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Tadalafil | TADALAFIL | NuCare Pharmaceuticals,Inc. | cf353da9-31c6-66c2-e053-2995a90a3bb0 | 2026-01-09 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | Northwind Health Company, LLC | f3092f5a-b976-91ab-e053-2995a90a9b50 | 2026-01-01 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | Northwind Health Company, LLC | f317fe1e-d7c4-fb8b-e053-2a95a90a5445 | 2026-01-01 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | Northwind Health Company, LLC | 0afd0728-256a-293b-e063-6394a90a3c5f | 2025-12-26 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | Northwind Health Company, LLC | f2a132af-d75e-2ca0-e053-2a95a90a332e | 2025-12-26 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED | 0ea97208-5afc-4943-b35c-ea850203a794 | 2025-12-19 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| ADCIRCA | TADALAFIL | United Therapeutics Corporation | ff61b237-be8e-461b-8114-78c52a8ad0ae | 2025-12-15 | Warnings, Adverse reactions | TADALAFIL |
| Tadalafil | TADALAFIL | NIVAGEN PHARMACEUTICALS, INC. | ca1d46e3-ad9b-48c7-bb7f-63ee678ccf7a | 2025-12-09 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | Quallent Pharmaceuticals Health LLC | dc14daa3-cae9-4751-9034-b0e9c18054b4 | 2025-11-30 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | Quallent Pharmaceuticals Health LLC | 84cb16c8-30ab-49f2-a6df-ec3c97bf6284 | 2025-11-20 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| tadalafil | TADALAFIL | PD-Rx Pharmaceuticals, Inc. | 6c680b37-d515-4fc2-83e6-411f1017e18c | 2025-10-14 | Warnings, Adverse reactions | tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | Ajanta Pharma USA Inc. | 7e4cdac1-42cc-4038-a86b-4890962ed806 | 2025-10-10 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | Ajanta Pharma USA Inc. | fceb8aaf-b4eb-4004-8ca4-f004eac6b314 | 2025-10-10 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| tadalafil | TADALAFIL | PD-RX Pharmaceuticals, Inc. | fc7596dd-42d3-af7c-e053-6294a90af01e | 2025-10-09 | Warnings, Adverse reactions | tadalafil TADALAFIL |
| tadalafil | TADALAFIL | PD-Rx Pharmaceuticals, Inc. | 5de70f00-00ac-4656-883e-d1e07d5f71d6 | 2025-10-09 | Warnings, Adverse reactions | tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | Preferred Pharmaceuticals Inc. | 2354c3e2-7b5f-4fdd-bbf2-7fa3c57686f8 | 2025-09-25 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| TADALAFIL | TADALAFIL | Preferred Pharmaceuticals Inc. | 66e24ced-0008-40cb-b242-9d9add1f665c | 2025-09-25 | Warnings, Adverse reactions | TADALAFIL TADALAFIL |
| Tadalafil | TADALAFIL | Preferred Pharmaceuticals Inc. | 761dc0f8-2f65-4615-ab49-a4bcffd40ce9 | 2025-09-25 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| TADALAFIL | TADALAFIL | Preferred Pharmaceuticals Inc. | 09ad27a1-3908-4533-b84c-7a7fd3514101 | 2025-09-25 | Warnings, Adverse reactions | TADALAFIL TADALAFIL |
| Tadalafil | TADALAFIL | Macleods Pharmaceuticals Limited | 4348b7db-e5b2-4e87-8cdd-674797a18890 | 2025-09-17 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.